# EDGAR Filing Document

**Accession Number:** 0001829667
**File Stem:** 0001213900-25-063278
**Filing Date:** 2025-7
**Character Count:** 9726
**Document Hash:** eb2bb67c9d0e7b1e9d1e0759d2490ffa
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-063278.hdr.sgml**: 20250711

**ACCESSION NUMBER**: 0001213900-25-063278

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250711

**DATE AS OF CHANGE**: 20250711

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Regencell Bioscience Holdings Ltd
- **CENTRAL INDEX KEY:** 0001829667
- **STANDARD INDUSTRIAL CLASSIFICATION:** MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-92718
- **FILM NUMBER:** 251119160

**BUSINESS ADDRESS:**
- **STREET 1:** 11/F FIRST COMMERCIAL BUILDING
- **STREET 2:** 33-35 LEIGHTON ROAD, CAUSEWAY BAY
- **CITY:** HONG KONG
- **STATE:** K3
- **ZIP:** 999077
- **BUSINESS PHONE:** 852 2155 0823

**MAIL ADDRESS:**
- **STREET 1:** 11/F FIRST COMMERCIAL BUILDING
- **STREET 2:** 33-35 LEIGHTON ROAD, CAUSEWAY BAY
- **CITY:** HONG KONG
- **STATE:** K3
- **ZIP:** 999077
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Regencell (BVI) Ltd
- **CENTRAL INDEX KEY:** 0001874958

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** D8

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 11/F FIRST COMMERCIAL BUILDING
- **STREET 2:** 33-35 LEIGHTON ROAD, CAUSEWAY BAY
- **CITY:** HONG KONG
- **STATE:** K3
- **ZIP:** 999077
- **BUSINESS PHONE:** 852 2155 0823

**MAIL ADDRESS:**
- **STREET 1:** 11/F FIRST COMMERCIAL BUILDING
- **STREET 2:** 33-35 LEIGHTON ROAD, CAUSEWAY BAY
- **CITY:** HONG KONG
- **STATE:** K3
- **ZIP:** 999077

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 7)**

**Regencell Bioscience Holdings Ltd**

*(Name of Issuer)*

**Ordinary Shares, $0.00001 Par Value**

*(Title of Class of Securities)*

**G7487R100**

*(CUSIP Number)*

**Yat-Gai Au**<br>9/F Chinachem Leighton Plaza<br>29 Leighton Road<br>Causeway Bay K3 00000<br>852 2155-0823

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**07/11/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **G7487R100** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Regencell (BVI) Limited** | Name of reporting person<br>**Regencell (BVI) Limited** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**D8** | Citizenship or place of organization<br>**D8** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**426429198.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**426429198.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**426429198.00** | Aggregate amount beneficially owned by each reporting person<br>**426429198.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**86.2%** | Percent of class represented by amount in Row (11)<br>**86.2%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

**Comment for Reporting Person:** The information had reflected the effect of the Issuer's 38-for-one forward stock split paid in the form of a stock bonus on June 13, 2025 (the "Forward Stock Split").

| **CUSIP No.** | **G7487R100** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Yat-Gai Au** | Name of reporting person<br>**Yat-Gai Au** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**PF** | Source of funds (See Instructions)<br>**PF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**HONG KONG** | Citizenship or place of organization<br>**HONG KONG** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**437896116.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**437896116.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**437896116.00** | Aggregate amount beneficially owned by each reporting person<br>**437896116.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**88.6%** | Percent of class represented by amount in Row (11)<br>**88.6%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** The information had reflected the effect of the Forward Stock Split.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Ordinary Shares, $0.00001 Par Value

**(b) Name of Issuer:**
Regencell Bioscience Holdings Ltd

**(c) Address of Issuer's Principal Executive Offices:**
9/F Chinachem Leighton, Plaza 29 Leighton Road, Causeway Bay, K3, 00000

This Amendment No. 7 to Schedule 13D (this "Amendment No. 7") amends and supplements the Schedule 13D filed with the Securities and Exchange Commission (the "SEC") on July 27, 2021 (as amended to date, the "Schedule 13D") by Mr. Yat-Gai Au ("Mr. Au"), a Hong Kong citizen, and Regencell (BVI) Limited, a limited liability company organized in British Virgin Islands ("Regencell (BVI) Limited," and together with Mr. Au, the "Reporting Persons"), with respect to the ordinary shares of Regencell Bioscience Holdings Limited (the "Company" or "Issuer"), with par value $0.00001 per share (the "Ordinary Shares"). Capitalized terms used herein without definition shall have the meaning set forth in the Schedule 13D.

**Item 5. Interest in Securities of the Issuer**

**(a)**
Items 5(a) and (b) of the Schedule 13D are hereby amended and restated in their entirety with the following:

The responses to Items 7 to 13 of each of the cover page of this Amendment No. 7 for the Reporting Persons are incorporated herein by reference.

Percentage is calculated based on the 494,488,908 ordinary shares of the Issuer issued and outstanding as of July 11, 2025, information provided by the Issuer, and such number had reflected the effect of the Forward Stock Split.

Mr. Au is the sole director and sole shareholder of Regencell (BVI) Limited and may be deemed to beneficially own the securities held by Regencell (BVI) Limited.

Mr. Au's spouse held of record 11,466,918 ordinary shares of the Issuer as of the date hereof and such number had reflected the effect of the Forward Stock Split. Mr. Au may be deemed to beneficially own the securities held by his spouse.

Except as set forth in this Item 5(a) and (b), to the knowledge of the Reporting Persons, none of the persons identified in Item 2 to Schedule 13D beneficially owns any Ordinary Shares of the Issuer.

**(b)**
See Item 5(a) above.

**(c)**
Item 5(c) of the Schedule 13D is hereby amended and restated in its entirety with the following:

Except as disclosed in this Item 5 of the Schedule 13D, no transactions in the Ordinary Shares were effected during the past sixty (60) days by the Reporting Persons, or to the knowledge of the Reporting Persons, any persons identified in Item 2 to Schedule 13D.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Regencell (BVI) Limited

**Signature:** /s/ Yat-Gai Au

**Name/Title:** Yat-Gai Au, Sole Director

**Date:** 07/11/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Yat-Gai Au

**Signature:** /s/ Yat-Gai Au

**Name/Title:** Yat-Gai Au

**Date:** 07/11/2025